Latest / The Dales Report | Trade to Black
Cannabis Enters the Execution Phase
Ever wonder how the CBD model actually works once cannabis rescheduling is implemented? Or how real-world medical evidence is finally starting to tell a clearer story around cannabinoids? And finally, what might be one of the biggest earnings prints yet from a major cannabis company — who is it, and why does it matter?We’re covering all of this in today’s episode.Segment One: Pulak Sharma, co-founder and CEO of Kazmira Therapeutics, will join us to break down how CBD coverage, prescribing, and delivery could realistically take shape in a post-rescheduling environment. We’ll also dig into…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.